Logan Reed
The Johnson & Johnson (J&J) COVID-19 vaccine, also known as the Janssen vaccine, was initially considered a game-changer due to its single-dose regimen and ease of storage. However, as of May 6, 2023, the J&J vaccine expired and is no longer available in the United States. In Germany, the federal vaccine agency announced that a single dose of the J&J vaccine would no longer be considered sufficient for full vaccination status. This decision was based on the need for extra protection against breakthrough infections, and those with only one dose of J&J were encouraged to get a second mRNA jab. While the J&J vaccine faced setbacks due to rare cases of adverse events, such as Guillain-Barré syndrome and blood clots, health authorities emphasized that the benefits of vaccination outweighed the risks.
Explore related products
What You'll Learn
Germany no longer considers J&J as fully vaccinated
Germany no longer considers individuals with a single dose of the Johnson & Johnson (J&J) vaccine, also known as Janssen, as fully vaccinated. This decision was announced by the country's vaccine authority, the Paul Ehrlich Institute (PEI), on January 15, 2022.
Previously, individuals who received the J&J vaccine were considered fully vaccinated after a single dose. However, the German government began recommending a second mRNA jab for individuals who had initially received the J&J vaccine. This additional jab was often interpreted as a booster shot.
As a result of this rule change, individuals who received only the single J&J shot, even with a subsequent booster, are no longer considered fully vaccinated under federal German rules. This new classification may impact their access to certain venues or activities, as proof of full vaccination or a negative coronavirus test may be required for entry.
The decision by the German authorities is based on studies indicating that the immune response generated by the J&J vaccine wanes quickly. The Robert Koch Institute, a German public health institute, currently recommends the J&J vaccine only for individuals aged 60 and older, and only as an initial shot.
It is important to note that the classification of the J&J vaccine may vary across different countries and regions. While Germany has implemented this change, other countries or regions may still recognize a single dose of the J&J vaccine as conferring full vaccination status.
South Africans and the Yellow Fever Vaccine
You may want to see also
Explore related products
J&J is a single-dose vaccine
The Johnson & Johnson (J&J) COVID-19 vaccine was initially believed to be a game-changer in the fight against the coronavirus because it only required one shot and did not need to be stored at freezing temperatures. This meant that it could be used to inoculate hard-to-reach populations such as those in rural areas and home-bound seniors. However, the J&J vaccine faced several setbacks. In April 2021, the CDC and FDA paused the vaccine for 10 days after six women under the age of 50 developed Cerebral Venous Sinus Thrombosis (CVST), a rare blood clot that forms in the venous sinuses of the brain, along with a low platelet-count condition known as thrombocytopenia.
Despite these rare cases, the J&J vaccine is generally safe, and the benefits of getting vaccinated outweigh the risks. In fact, most people who suffer from vaccine-induced Guillain-Barré—a rare autoimmune disease that can cause permanent nerve damage—fully recover with proper treatment.
While the J&J vaccine was once considered a single-dose vaccine, some countries now recommend a second dose to complete "basic immunisation." For example, in Germany, people who have received the J&J vaccine are advised to get a second mRNA jab, and a third booster shot to be considered fully vaccinated and exempt from COVID-related restrictions. Similarly, in the United States, those who received the J&J shot are encouraged to follow up with one of the currently available updated vaccines to ensure they are up-to-date with their COVID-19 vaccinations.
It is important to note that the J&J vaccine is no longer available in the US as of May 6, 2023. However, individuals who received the J&J vaccine in the past and have not received any additional doses may still be considered fully vaccinated in certain contexts, depending on the specific requirements and guidelines of their location.
Egg Allergy and MMR Vaccine: What's the Link?
You may want to see also
Explore related products
J&J is linked to rare autoimmune diseases
The Johnson & Johnson (J&J) COVID-19 vaccine expired on May 6, 2023, and is no longer available in the US. Those who received the J&J shot are considered fully vaccinated if they follow the recommendations for getting one of the currently available updated vaccines.
The J&J vaccine has been linked to rare autoimmune diseases in some cases. Vanessa Abraham, a 45-year-old mother, experienced a severe case of a rare neurological disease that took away her ability to speak and left her paralysed. Abraham had spent over 15 years helping children overcome speech obstacles and teaching them to talk. In another case, a woman named Vanessa Abraham (seemingly unrelated to the first individual) contracted a rare disease linked to the COVID-19 vaccine and lost her ability to speak. This disease was identified as GBS (Guillan-Barre Syndrome), which affects about one in 100,000 people in the US annually. GBS is believed to be triggered by an immune system response to an infection and has been linked to other vaccines and infections as well. While there is no known cure for GBS, early treatment with therapies such as plasma exchange and immunoglobulin injections can help alleviate symptoms and reduce recovery time.
The Varicella Vaccine: What's in a Name?
You may want to see also
Explore related products
J&J was paused by the CDC and FDA in April 2021
The Johnson & Johnson (J&J) COVID-19 vaccine was paused by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) on April 13, 2021. This decision was made in response to reports of adverse effects in some vaccinated individuals. Specifically, there were concerns about cases of cerebral venous sinus thrombosis (CVST), a rare form of blood clot known as thrombocytopenia syndrome (TTS). At the time of the pause, there had been 15 reported cases of TTS out of over 8 million vaccine doses administered in the United States.
The pause on the J&J vaccine was lifted on April 23, 2021, just 10 days after it was initially implemented. The FDA stated that the benefits of the J&J vaccine outweighed its potential risks for individuals aged 18 years and older. However, the pause had a significant impact on public perception and confidence in the vaccine. Careful messaging and a coordinated communication strategy were necessary to mitigate the potential decrease in trust surrounding COVID-19 vaccines.
Despite the lift on the pause, the J&J vaccine faced further limitations and scrutiny. By December 2021, the FDA advised that mRNA COVID-19 vaccines, such as those produced by Pfizer and Moderna, were preferred over the J&J vaccine. This recommendation was based on accumulating data that indicated an increased risk of TTS associated with the J&J vaccine. As of May 2022, the FDA and CDC had identified 60 confirmed cases of TTS, including nine fatal cases, among individuals who had received the J&J vaccine.
It is important to note that the J&J vaccine is no longer available in the United States as of May 6, 2023. Individuals who previously received the J&J vaccine are considered up-to-date if they follow the recommended guidelines for obtaining one of the currently available updated vaccines. While the J&J vaccine may have faced challenges and is no longer in use, it is important to recognize that vaccines continue to play a crucial role in preventing severe illness, hospitalization, and death from COVID-19 and its variants.
Anti-Vaccine Shirts: Fake Photo or Real?
You may want to see also
J&J is no longer available in the US
The Johnson & Johnson (Janssen) COVID-19 vaccine is no longer available in the United States. The last batch of the J&J vaccine expired in May 2023, and the Centers for Disease Control and Prevention (CDC) instructed providers to dispose of any unused doses.
The J&J vaccine was once hoped to be an important tool in the US's fight against COVID-19, especially since it was a one-shot dose that could help those without access to mRNA vaccines. However, concerns emerged in April 2021 about a possible link between the vaccine and a rare but serious blood clotting disorder called thrombosis with thrombocytopenia (TTS). This concern prompted the government to pause the J&J vaccine rollout after six women who had received the shot developed rare blood clots, and one of them died.
The clotting condition associated with the J&J vaccine is unusual. Thrombosis occurs when blood clots block veins or arteries, and thrombocytopenia is characterised by abnormally low platelet levels in the blood. This combination has surprised medical experts, who note that the mechanism of these clots has been quite unusual.
While the J&J vaccine is no longer available, those who received the shot are considered up-to-date if they follow the recommendations for getting one of the currently available updated vaccines.
Free Vaccines at Walgreens: What's the Deal?
You may want to see also
Frequently asked questions
The J&J vaccine was paused by the CDC and FDA in 2021 and has since expired as of May 6, 2023, and is no longer available in the US. Those who received the J&J shot are considered up-to-date if they follow the recommendations for getting one of the currently available updated vaccines.
No, since January 15, 2022, a single dose of J&J should no longer count as full vaccination, according to the Paul Ehrlich Institute (PEI), Germany's vaccine authority.
The Johnson & Johnson Janssen COVID-19 vaccine was believed to be a game-changer as it only required one shot and did not need to be stored at freezing temperatures.
The J&J vaccine was paused by the CDC and FDA in 2021 after reports of a link to a rare autoimmune disease called Guillain-Barré syndrome.
Although the J&J vaccine is linked to a rare autoimmune disease, the FDA emphasizes that the benefits of getting vaccinated outweigh the risks. Most people suffering from Guillain-Barré fully recover.
